Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on November 6, 2008
Japanese Journal of Clinical Oncology 2008 38(12):793-802; doi:10.1093/jjco/hyn116
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
38/12/793    most recent
hyn116v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Matsumura, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumura, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

Polymeric Micellar Delivery Systems in Oncology

Yasuhiro Matsumura

Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

For reprints and all correspondence: Yasuhiro Matsumura, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. E-mail: yhmatsum{at}east.ncc.go.jp

Received September 1, 2008; accepted September 22, 2008

The purpose of drug delivery systems in cancer chemotherapy is to achieve selective delivery of anti-cancer agents to cancer tissue at an effective concentrations for the appropriate duration of time, so that we may be able to reduce the adverse effects of a drug and simultaneously enhance the anti-tumor effect. Polymeric micelles were expected to increase the accumulation of drugs in tumor tissues utilizing the enhanced permeability and retention effect and to incorporate various kinds of drugs into the inner core by chemical conjugation or physical entrapment with relatively high stability. The size of the micelles can be controlled within the diameter range of 20–100 nm, to ensure that the micelles do not pass through normal vessel walls; therefore, a reduced incidence of the side effects of the drugs may be expected due to the decreased volume of distribution. There are several anti-cancer agent-incorporated micelle carrier systems under clinical evaluation. Phase 1 studies of a cisplatin-incorporated micelle, NC-6004 and an SN-38-incorporated micelle, NK012, are now underway. A Phase 2 study of a paclitaxel-incorporated micelle, NK105, against stomach cancer is also underway.

Key Words: DDS • polymer micelles • clinical trial • EPR effect


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.